author-photo

Huiling Pei

Janssen Pharmaceutica

47

Papers

352

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA

2022
Show All
- Source
- Cite
- Save
Citations (0)
Key issues and algorithms of multiple-input-multiple-output over-the-air testing in the multi-probe anechoic chamber setup.

2022 Sci. China Inf. Sci.
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (1)
Clinical Utility of Wearable Sensors and Patient-Reported Surveys in Patients With Schizophrenia: Noninterventional, Observational Study.

2021 JMIR mental health
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Effet de l’association daratumumab (Dara) plus bortézomib/cyclophosphamide/dexaméthasone (VCd) sur la fonction rénale et les questionnaires de qualité de vie évalués par le patient (PRO) dans l’amylose AL nouvellement diagnostiquée avec atteinte rénale : résultats de l’étude de phase 3 ANDROMEDA

2021 Nephrologie & Therapeutique
Show All
- Source
- Cite
- Save
Citations (0)
Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (1)